For professionals and analysts
Our main technology
Functional selection of stem cells through an apoptotic process
An example of one potential use of ApoGraft™
Functional Selection of Stem Cells
Prior to animal studies, as a part of an in vitro campaign, studies were performed to define the most relevant effector molecules (TNF superfamily: Fas ligand, TRAIL etc.), the concentrations and conditions for the murine studies. Following that, a large number of animal studies were performed in order to test the technology in murine and human transplant models, while using various sources of human hematopoietic cells (mobilized peripheral blood, bone marrow and umbilical cord blood), relevant donor types (self, family and unrelated) and measuring the relevant adverse effects (GvHD, mortality, engraftment and anti-tumor effect).
These findings support Cellect product claims for:
The goals for the clinical development are therefore:
Graft versus Host disease (GvHD) is a common complication of allogeneic (non-related) as well as haploidentical (family member) stem-cell transplantations in which T-cells present in the graft launch an immunologic attack on the host. GvHD reactions are very common, and in most cases they create a debilitating chronic disease which requires continuous immune suppression and may evolve into a life-threatening acute disease. GvHD is the most serious drawback of bone marrow transplantation and the main reason why this life saving procedure is currently used only for life threatening conditions (mainly cancer).
As a start-up company, Cellect Biotechnology focuses its resources to the development of the Apograft product. However, using its affiliated laboratory, the company’s scientific team is pursuing two lines of research:
Apoptosis in hematopoietic progenitors
GvHD prophylaxis and treatment
GvHD versus GvT